Literature DB >> 16321859

N-RAS and K-RAS gene mutations in Brazilian patients with multiple myeloma.

Manoela M Ortega1, Rosa M D Faria, Edson S Shitara, Angela M Assis, Dulcinéia M Albuquerque, José S R Oliveira, Maria A E Noguti, José R Faria, Fernando F Costa, Carmen S P Lima.   

Abstract

Point mutations affecting codons 12, 13 (exon 1) and 61 (exon 2) of the N-RAS gene and codons 12 and 13 (exon 1) of the K-RAS gene are identified in approximately 30.0% and 10.0%, respectively, of multiple myeloma (MM) patients living in the northern hemisphere. To date, there are no reports about the prevalence of RAS gene mutations in MM Brazilian patients, and this comprised the aim of the present study. DNA from bone marrow aspirates of 252 patients with MM (139 males and 113 females; aged 59.33 +/- 11.95 years) were investigated for whole exons 1 and 2 of the N-RAS gene and whole exon 1 of the K-RAS gene by direct sequencing of DNA amplified in vitro by the polymerase chain reaction. Fifty-three out of 252 (21.03%) MM patients presented RAS mutations. Heterozygous mutations at codons 4, 10 (exon 1), 61 and 65 (exon 2) of the N-RAS gene were identified in seven out of 252 (2.78%) patients. K-RAS heterozygous mutations at codons 7, 12, 13 (exon 1) were seen in 46 out of 252 (18.25%) patients. To the best of our knowledge, the mutation at codon 7 of K-RAS gene is reported for the first time in MM. Taken together, these results suggest that Brazilian MM patients are characterized by: (i) a low prevalence of RAS mutation and (ii) RAS mutations located at distinct regions of the critical codons of the N-RAS and K-RAS genes.

Entities:  

Mesh:

Year:  2006        PMID: 16321859     DOI: 10.1080/10428190500300969

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

Review 1.  How I treat plasma cell leukemia.

Authors:  Niels W C J van de Donk; Henk M Lokhorst; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

2.  Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.

Authors:  George Mulligan; David I Lichter; Alessandra Di Bacco; Stephen J Blakemore; Allison Berger; Erik Koenig; Hugues Bernard; William Trepicchio; Bin Li; Rachel Neuwirth; Nibedita Chattopadhyay; Joseph B Bolen; Andrew J Dorner; Helgi van de Velde; Deborah Ricci; Sundar Jagannath; James R Berenson; Paul G Richardson; Edward A Stadtmauer; Robert Z Orlowski; Sagar Lonial; Kenneth C Anderson; Pieter Sonneveld; Jesús F San Miguel; Dixie-Lee Esseltine; Matthew Schu
Journal:  Blood       Date:  2013-12-11       Impact factor: 22.113

3.  Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia.

Authors:  Michael A Linden; Nicole Kirchhof; Cathy S Carlson; Brian G Van Ness
Journal:  Exp Hematol       Date:  2011-11-23       Impact factor: 3.084

Review 4.  Plasma cell leukemia.

Authors:  Flavio Albarracin; Rafael Fonseca
Journal:  Blood Rev       Date:  2011-02-03       Impact factor: 8.250

5.  Genetic aberrations and survival in plasma cell leukemia.

Authors:  R E Tiedemann; N Gonzalez-Paz; R A Kyle; R Santana-Davila; T Price-Troska; S A Van Wier; W J Chng; R P Ketterling; M A Gertz; K Henderson; P R Greipp; A Dispenzieri; M Q Lacy; S V Rajkumar; P L Bergsagel; A K Stewart; R Fonseca
Journal:  Leukemia       Date:  2008-01-24       Impact factor: 11.528

Review 6.  Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis.

Authors:  Victor H Jimenez-Zepeda; Virginia J Dominguez-Martinez
Journal:  Int J Hematol       Date:  2009-03-27       Impact factor: 2.490

Review 7.  B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies.

Authors:  José P Vaqué; Nerea Martínez; Ana Batlle-López; Cristina Pérez; Santiago Montes-Moreno; Margarita Sánchez-Beato; Miguel A Piris
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.